09:30 AM EDT, 10/12/2026 (MT Newswires) -- Lonza Group (LONN.SW) and South Korean biopharmaceutical company Qurient signed an exclusive dual-payload platform licensing agreement, according to a Monday release. The deal allows the Swiss healthcare-focused manufacturing company to use Qurient's cyclin-dependent kinase 7, or CDK7, inhibitors for dual-payload antibody-drug conjugate applications targeting cancer.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.